Participated · Seed · Jun 2023

AvoMD builds a clinical AI platform designed to synthesize patient data, surface evidence-based guidance, and support clinicians with end-to-end AI copilots embedded in the EHR. The company positions its product to reduce clinician friction caused by fragmented datasets and multiple applications, aiming to drive measurable improvements in outcomes, cost savings, revenue, and operational efficiency. AvoMD announced a strategic partnership with DynaMed from EBSCO Clinical Decisions to integrate trusted evidence-based knowledge into the EHR via Ask Avo. The business emphasized clinician-centric design, saying it delivers results “with love, not alerts.” Financially, AvoMD has secured a $10M Series A to accelerate product development and commercialization. The announcement credits engaged customers, partners, and its team for supporting the company's growth.

Participated · Series B · May 2021

HiberCell develops therapeutic molecules aimed at preventing cancer relapse and metastasis by targeting stress biology and innate immunity. The company’s lead candidate, HC-5404-FU, is the first from its 'stress modulator' platform and reportedly has direct anti-tumor activity while reprogramming the immunosuppressive tumor microenvironment. HiberCell views cancer as a chronic disease and is focused on therapies that address relapse and metastasis. The company will use proceeds from its recent financings to support clinical development of these novel therapeutics. HiberCell is led by Co-Founder and CEO Alan Rigby, Ph.D. and is based in New York City. HiberCell develops therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers to prevent relapse and metastasis. The company is exclusively focused on DTC-directed drug discovery and development. At launch, Alan Rigby, Ph.D., will serve as president and chief scientific officer; Ari Nowacek, Ph.D., M.D., will serve as vice president of operations and business development; and Mark Mulvihill, Ph.D., will serve as vice president of chemistry and drug discovery. Its team comprises cancer scientists, venture capitalists and drug developers. HiberCell raised $60.75M in Series A financing to advance its therapeutic programs. The company has assembled a board and a scientific advisory board with academic and industry leaders to guide its programs.

Led · Seed · Aug 2020

Trellus Health provides a multidisciplinary connected care platform that coordinates clinical and behavioral health to support whole-person care for chronic conditions, initially focused on IBD including Crohn’s disease and ulcerative colitis. The company leverages a patent-pending GRITT-IBDTM resilience assessment and a personalized treatment methodology developed at Mount Sinai to support patient resilience and wellness. Trellus aims to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system through its connected care approach. The company was co-founded by Marla Dubinsky, MD, and Laurie Keefer, PhD, and is led by CEO Monique Fayad. Financially, Trellus announced a $5M seed funding round to support commercialization and growth efforts. It has entered an exclusive multi-year contract with Mount Sinai Health System to commercialize its GRITT-IBDTM methodology.

Participated · Series B · Nov 2018

Jump Technologies is an Eagan, Minn.-based hospital supply chain solutions provider led by CEO John Freund. The company offers JumpStock, a cloud-based hospital supply chain software solution that integrates with any ERP system. JumpStock integrates into clinical workflows and delivers reports that allow clinicians and supply-chain professionals to make informed decisions about supply utilization across facilities, including high-cost areas such as operating and procedure rooms. The platform enables hospitals to standardize supply utilization, save money, and reallocate funds to clinical resources and technology while ensuring clinicians have the right supplies when and where needed. The company plans to use recent funding to expand its national sales and product development efforts. Jump Technologies is an Eagan, MN-based software company that provides cloud-based supply chain solutions for health systems. Its offerings include JumpStock Inventory Management and InnerTrack Receiving & Package Tracking, which automate supply management from demand through use and replenishment. The solutions are designed to reduce overstocking, stock-outs, hoarding and waste while increasing inventory turns, enabling data-driven decision making and improving forecasting and planning. The company is led by CEO John Freund. Jump closed a $3.5M funding round from Black Granite Capital LLC and intends to use the funds to expand and enhance its solutions and to grow its sales, customer success, development and quality assurance teams.

Participated · Series C · Oct 2018

Gauss Surgical provides Triton, a platform that measures surgical blood loss in real time on the iPad using digital imaging and machine learning. The company has received de novo approval from the U.S. Food and Drug Administration and a European CE mark for the device. Triton has been adopted by 50 hospitals that together perform more than 200,000 infant deliveries each year. Gauss plans to use new funding to accelerate Triton adoption in hospitals and to develop additional AI-driven applications for the operating room. The company is led by founder and CEO Siddarth Satish and is based in Los Altos, California. Its recent financing improves its runway to scale clinical deployment and product development. Gauss Surgical developed Triton, a real-time platform for monitoring surgical blood loss that combines computer vision and machine learning. Triton supplies clinicians with accurate blood loss assessments to support surgical decision-making. The platform holds four FDA clearances and has received CE Mark approval. Triton is in clinical use at several U.S. health systems including HackensackUMC, Cedars-Sinai Medical Center, the MemorialCare Health System, and UC Irvine Medical Center. The company is led by founder and CEO Siddarth Satish and recently closed a $12.6M Series B. Gauss has raised $24.6M in total funding to date. Gauss Surgical develops a digital health app that quantifies surgical blood loss by measuring blood collected in canisters. The app received FDA 510(k) clearance a few months before the latest fundraise. Management says the tool can help reduce clinical and staff burnout by automating blood-loss measurement. Target use cases called out include obstetrics, patients with severe burns, and procedures prone to heavy blood loss such as orthopedic, cardiovascular, and pediatric surgery. The company has seen rising interest from prospective corporate and strategic investors exploring digital health solutions for hospitals. Gauss plans to use new funding to support sales and marketing for the app rollout.